{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:20:30Z","timestamp":1789395630975,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"DOI":"10.1007\/s10637-026-01636-w","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:40:20Z","timestamp":1789393220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["First-in-human phase I study of DT-9081, a selective EP4 receptor antagonist, in advanced solid tumors"],"prefix":"10.1007","author":[{"given":"Rachel","family":"Galot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Castel-Ajgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Kotecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Jungels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Delord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iphigenie","family":"Korakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"El-Farouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Jouffroy-Zeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Quesnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelkrim","family":"Taamma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Maurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lola","family":"Lecru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Mousson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orph\u00e9e","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Blayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Lenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Schann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Cuillerot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Le Tourneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6369-9742","authenticated-orcid":false,"given":"Jean-Pascal","family":"Machiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"1636_CR1","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA (2021) Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184:5309\u20135337. https:\/\/doi.org\/10.1016\/j.cell.2021.09.020","journal-title":"Cell"},{"issue":"2\u20133","key":"1636_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10555-018-9752-y","volume":"37","author":"D Tong","year":"2018","unstructured":"Tong D, Liu Q, Wang LA et al (2018) The roles of the COX2\/PGE2\/EP axis in therapeutic resistance. Cancer Metastasis Rev 37(2\u20133):355\u2013368. https:\/\/doi.org\/10.1007\/s10555-018-9752-y","journal-title":"Cancer Metastasis Rev"},{"key":"1636_CR3","doi-asserted-by":"publisher","first-page":"5239","DOI":"10.1111\/bph.13331","volume":"172","author":"G O'Callaghan","year":"2015","unstructured":"O\u2019Callaghan G, Houston A (2015) Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? Br J Pharmacol 172:5239\u20135250. https:\/\/doi.org\/10.1111\/bph.13331","journal-title":"Br J Pharmacol"},{"issue":"1","key":"1636_CR4","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1896643","volume":"10","author":"Y Wang","year":"2021","unstructured":"Wang Y, Cui L, Georgiev P et al (2021) Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells. Oncoimmunology 10(1):e1896643. https:\/\/doi.org\/10.1080\/2162402X.2021.1896643","journal-title":"Oncoimmunology"},{"key":"1636_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29606-9","volume":"13","author":"CR Bell","year":"2022","unstructured":"Bell CR, Pelly VS, Moeini A et al (2022) Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations. Nat Commun 13:2063. https:\/\/doi.org\/10.1038\/s41467-022-29606-9","journal-title":"Nat Commun"},{"key":"1636_CR6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12935-015-0260-7","volume":"15","author":"B Liu","year":"2015","unstructured":"Liu B, Qu L, Yan S (2015) Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int 15:106. https:\/\/doi.org\/10.1186\/s12935-015-0260-7","journal-title":"Cancer Cell Int"},{"key":"1636_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.pharmthera.2013.03.006","volume":"138","author":"V Konya","year":"2013","unstructured":"Konya V, Marsche G, Schuligoi R, Heinemann A (2013) E-type prostanoid receptor 4 (EP4) in disease and therapy. Pharmacol Ther 138:485\u2013502. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.03.006","journal-title":"Pharmacol Ther"},{"key":"1636_CR8","doi-asserted-by":"publisher","first-page":"33500","DOI":"10.18632\/oncotarget.5589","volume":"6","author":"J Chang","year":"2015","unstructured":"Chang J, Vacher J, Yao B et al (2015) Prostaglandin E receptor 4 (EP4) promotes colonic tumorigenesis. Oncotarget 6:33500\u201333511. https:\/\/doi.org\/10.18632\/oncotarget.5589","journal-title":"Oncotarget"},{"key":"1636_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1338239","volume":"6","author":"DI Albu","year":"2017","unstructured":"Albu DI, Wang Z, Huang KC et al (2017) EP4 antagonism by E7046 diminishes myeloid immunosuppression and synergizes with Treg-reducing IL-2-diphtheria toxin fusion protein in restoring anti-tumor immunity. Oncoimmunology 6:e1338239. https:\/\/doi.org\/10.1080\/2162402X.2017.1338239","journal-title":"Oncoimmunology"},{"key":"1636_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/cas.15574","volume":"114","author":"S Iwasa","year":"2023","unstructured":"Iwasa S, Koyama T, Nishino M et al (2023) First-in-human study of ONO-4578, an antagonist of prostaglandin E2 receptor 4, alone and with nivolumab in solid tumors. Cancer Sci 114:211\u2013220. https:\/\/doi.org\/10.1111\/cas.15574","journal-title":"Cancer Sci"},{"key":"1636_CR11","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1111\/cas.70130","volume":"116","author":"A Kawazoe","year":"2025","unstructured":"Kawazoe A, Yamaguchi K, Hamaguchi T et al (2025) ONO-4578 plus nivolumab in unresectable advanced or recurrent gastric\/gastroesophageal junction cancer. Cancer Sci 116:2523\u20132536. https:\/\/doi.org\/10.1111\/cas.70130","journal-title":"Cancer Sci"},{"key":"1636_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000222","volume":"8","author":"DS Hong","year":"2020","unstructured":"Hong DS, Parikh A, Shapiro GI et al (2020) First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers. J Immunother Cancer 8:e000222. https:\/\/doi.org\/10.1136\/jitc-2019-000222","journal-title":"J Immunother Cancer"},{"key":"1636_CR13","doi-asserted-by":"crossref","unstructured":"Blayo AL, Hommet G, Fer M et al (2026) Discovery of DT-9081, a potent and orally bioavailable small molecule antagonist of the EP4 receptor for the treatment of solid cancers. J Med Chem. Accepted for publication","DOI":"10.1021\/acs.jmedchem.6c00863"},{"key":"1636_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"1636_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/cts.12497","volume":"11","author":"Y Jin","year":"2018","unstructured":"Jin Y, Smith C, Hu L, Coutant DE et al (2018) LY3127760, a selective prostaglandin E4 (EP4) receptor antagonist, and celecoxib: a comparison of pharmacological profiles. Clin Transl Sci 11:46\u201353. https:\/\/doi.org\/10.1111\/cts.12497","journal-title":"Clin Transl Sci"},{"key":"1636_CR16","doi-asserted-by":"publisher","first-page":"G1097","DOI":"10.1152\/ajpgi.00280.2010","volume":"299","author":"I Dey","year":"2010","unstructured":"Dey I, Lejeune M, Chadee K (2010) Role of EP4 receptor and prostaglandin transporter in prostaglandin E2-induced alteration in colonic epithelial barrier integrity. Am J Physiol Gastrointest Liver Physiol 299:G1097\u2013G1105. https:\/\/doi.org\/10.1152\/ajpgi.00280.2010","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1636_CR17","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1172\/JCI14459","volume":"109","author":"K Kabashima","year":"2002","unstructured":"Kabashima K, Saji T, Murata T et al (2002) The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 109:883\u2013893. https:\/\/doi.org\/10.1172\/JCI14459","journal-title":"J Clin Invest"},{"key":"1636_CR18","doi-asserted-by":"publisher","first-page":"12752","DOI":"10.1074\/jbc.M212097200","volume":"278","author":"T Hoshino","year":"2003","unstructured":"Hoshino T, Tsutsumi S, Tomisato W et al (2003) Prostaglandin E2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation. J Biol Chem 278:12752\u201312758. https:\/\/doi.org\/10.1074\/jbc.M212097200","journal-title":"J Biol Chem"},{"key":"1636_CR19","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.immuni.2020.10.020","volume":"53","author":"E Bonavita","year":"2020","unstructured":"Bonavita E, Bromley CP, Jonsson G et al (2020) Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade. Immunity 53:1215-1229.e8. https:\/\/doi.org\/10.1016\/j.immuni.2020.10.020","journal-title":"Immunity"},{"issue":"Suppl","key":"1636_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1200\/JCO.2024.42.3_suppl.93","volume":"42","author":"A Kawazoe","year":"2024","unstructured":"Kawazoe A, Takashima A, Matsuoka H et al (2024) ONO-4578 plus nivolumab in metastatic colorectal cancer. J Clin Oncol 42(Suppl):93","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"1636_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100273","volume":"16","author":"AW Tolcher","year":"2022","unstructured":"Tolcher AW, Spigel DR, Leal AD et al (2022) A phase Ib study to evaluate IK-007 in combination with pembrolizumab in patients with advanced microsatellite stable colorectal cancer. Immuno-Oncol Technol 16(Suppl 1):100273. https:\/\/doi.org\/10.1016\/j.iotech.2022.100273","journal-title":"Immuno-Oncol Technol"},{"issue":"Suppl 16","key":"1636_CR22","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1200\/JCO.2023.41.16_suppl.3107","volume":"41","author":"SV Ulahannan","year":"2023","unstructured":"Ulahannan SV, Powderly JD, Johnson ML et al (2023) A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors. J Clin Oncol 41(Suppl 16):3107. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.3107","journal-title":"J Clin Oncol"},{"key":"1636_CR23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-26-01072","author":"I Nakayama","year":"2026","unstructured":"Nakayama I, Ryu MH, Lim SH et al (2026) EP4 antagonist ONO-4578 plus nivolumab and chemotherapy in HER2-negative unresectable advanced or recurrent gastric or gastroesophageal junction cancer. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO-26-01072","journal-title":"J Clin Oncol"},{"key":"1636_CR24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1158\/1078-0432.CCR-24-2611","volume":"31","author":"F Pietrantonio","year":"2025","unstructured":"Pietrantonio F, Morano F, Niger M, Ghelardi F, Chiodoni C, Palazzo M, Nichetti F, Manca P, Cristarella E, Doldi V, Zaffaroni N, Sabella G, Brambilla N, Benincasa E, Giacovelli G, Vitalini C, Girolami F, Rovati LC (2025) The prostaglandin EP4 antagonist vorbipiprant combined with PD-1 blockade for refractory microsatellite-stable metastatic colorectal cancer: a phase Ib\/IIa trial. Clin Cancer Res 31:649\u2013658. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2611","journal-title":"Clin Cancer Res"},{"key":"1636_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109669","volume":"185","author":"L Wyrwicz","year":"2023","unstructured":"Wyrwicz L, Saunders M, Hall M et al (2023) AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer. Radiother Oncol 185:109669. https:\/\/doi.org\/10.1016\/j.radonc.2023.109669","journal-title":"Radiother Oncol"},{"key":"1636_CR26","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1158\/2767-9764.CRC-23-0249","volume":"3","author":"BJ Francica","year":"2023","unstructured":"Francica BJ, Holtz A, Lopez J et al (2023) Dual blockade of EP2 and EP4 signaling is required for optimal immune activation and antitumor activity against prostaglandin-expressing tumors. Cancer Res Commun 3:1486\u20131500. https:\/\/doi.org\/10.1158\/2767-9764.CRC-23-0249","journal-title":"Cancer Res Commun"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01636-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01636-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01636-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:40:24Z","timestamp":1789393224000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-026-01636-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":26,"alternative-id":["1636"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01636-w","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"7 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Financial interests: Samira El Farouk, Anne Quesnel, Orph\u00e9e Blanchard, Anne-Laure Blayo, Nathalie Lenne, Thomas Maurin, Stephan Schann, and Jean-Marie Cuillerot are employees of Kainova Therapeutics. Nathalie Lenne and Stephan Schann hold stocks in Kainova Therapeutics. Stephan Schann is also co-inventor of patent applications related to Kainova Therapeutics. Claire Jouffroy-Zeller, Antoine Mousson, and Carolina Duarte are former employees of Domain Therapeutics (now Kainova Therapeutics). Carolina Duarte is currently employed by Viatris Innovation GmbH. Lola Lecru is an employee of Ipsen and former biomarker leader at Domain Therapeutics. Xavier Leroy is a shareholder in entities developing therapeutic programs related to the subject of this study. Jean-Marie Cuillerot also holds stocks in BMS, Dragonfly Therapeutics, and Skyhawk Therapeutics. Abdelkrim Taamma is affiliated with AKT Clinical Development Consulting.Rachel Galot has received speaker honoraria (managed by her institution) from MSD and BMS and travel support from Merck, MSD, and Daiichi Sankyo. Zahra Castel-Ajgal has participated in advisory boards for Johnson &; Johnson and Astellas and has received travel grants or speaker honoraria from Bayer, Novartis, and Johnson &; Johnson. Nuria Kotecki has participated in advisory boards for AstraZeneca and Daiichi Sankyo and has received travel grants or speaker honoraria from AstraZeneca and Gilead. Christiane Jungels has received travel grants from PharmaMar, Bayer, and Ipsen. Iphigenie Korakis has received speaker honoraria from MSD and Pierre Fabre and has served as principal investigator for studies sponsored by AbbVie, Amgen, Anaveon, Astellas, C4 Therapeutics, Daiichi Sankyo, Dragonfly Therapeutics, Fore Therapeutics, Greywolf Therapeutics, ImCheck Therapeutics, and Merck. Jean-Pierre Delord has received speaker or advisory board honoraria (managed by his institution) from BMS, Merck Serono, MSD, Pierre Fabre, Roche, Amgen, and AstraZeneca and research grants from Genentech, MSD, and Transgene. Christophe Le Tourneau has participated in advisory boards for BMS, MSD, Transgene, LEO Pharma, Roche, Merus, Bicara, Johnson &; Johnson, GSK, AstraZeneca, DOB Pharmaceuticals, Owkin, Genmab, Immutep, ALX Oncology, Merck Serono, Pfizer, Aveo, Seagen, Exscientia, Maxivax, and Kumar Therapeutics. Jean-Pascal Machiels has received advisory board or speaker honoraria (managed by his institution) from Pfizer, Roche, Bayer, Merck Serono, Boehringer Ingelheim, BMS, Novartis, Incyte, Cue Biopharma, ALX Oncology, iTeos, eTheRNA, Nektar, F-Star, Seagen, Genmab, Astellas, CureVac, MSD, GSK, Merus, Ipsen, and Anaveon and research funding from Amgen, BMS, Pfizer, Gilead, Sanofi, and MSD.The remaining authors declare no relevant financial or non-financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}